|[August 26, 2014]
AB SCIEX and Dalton Pharma Services Collaborate to Advance Antibody-Drug Conjugate Analysis
TORONTO --(Business Wire)--
AB SCIEX and Dalton Pharma Services (Dalton) announced today a research
collaboration to develop Antibody-Drug Conjugate (ADC (News - Alert)) analysis
capabilities. This will include development of more definitive and
comprehensive method for the identification of drug loading and position
of conjugation on macromolecules. This collaboration is part of AB
SCIEX's commitment to support the growing movement to bring targeted
antibody-based therapies to market.
Our collective goal is to help our customers bring drugs from concept to
market faster. The collaboration provides AB SCIEX, a global leader in
life science analytical technologies, with the specialized synthetic
conjugation capabilities of Dalton. The research includes the
preparation and characterization of ADC's by Dalton scientists working
with AB SCIEX experts to develop standardized analytical procedures on
5600+ system with SelexION™ technology and the new TripleTOF®
6600 platform for determining the chemical structures of conjugated
"A key challenge for developing successful Antibody-Drug Conjugate
medicines is understanding the structure and payload of the final
molecule. Determining where the drug attaches to a particular antibody
early in its development and the number of drug molecules on the
antibody ar important indicators of the likely success of a new ADC,"
explained Tan Quach, Chemistry Manager at Dalton Pharma Services.
"Recent advances in mass spectrometry have provided a solution to answer
the challenging questions in terms of understanding ADC drug development
and working within a biological matrix," said Chris Radloff, Vice
President, LC/ MS Business at AB SCIEX. "Utilizing these molecules
is difficult and by forming this partnership, ADC developers can now
reduce complications, and obtain accurate results that will ultimately
lead to safer, more effective therapies."
Results of the first phase of the collaboration were featured at ASMS
2014 in Baltimore. The partnership will continue to co-develop
standardized analytical procedures utilizing the MS technology that
delivers consistent results when compared with ELISA and publish
technical papers over the next upcoming months.
Dalton Chemical Laboratories, Inc., o/a Dalton Pharma Services, is a GMP
contract manufacturer that supplies chemistry, analytical and
formulation development services to the biotechnology and pharmaceutical
industries in the areas of medicinal chemistry and fine chemical
manufacture. Dalton offers custom conjugation services as a tool for
drug delivery, including development of antibody-drug conjugates (ADCs).
Dalton provides cGMP manufacturing of solid dosage forms and aseptic
filling services to its customers at any stage of the regulatory process
(Phase I, II, III or commercial). In its modern cGMP facilities, Dalton
performs sterile powder filling and sterile crystallizations, and
produces sterile active pharmaceutical ingredients (APIs) at the gram or
kilogram scale. Dalton conducts aseptic fills to produce batches of
finished drug product in vials or syringes, either aseptically filled or
terminally sterilized, under fully validated conditions. In addition,
Dalton's analytical chemistry laboratory offers method development,
validation and ICH stability programs to its clients. Further
information can be found at http://www.dalton.com.
About AB SCIEX
AB SCIEX helps to improve the world we live in by enabling scientists
and laboratory analysts to find answers to the complex analytical
challenges they face. The company's global leadership and world-class
service and support in the liquid chromatography-mass spectrometry
industry have made it a trusted partner to thousands of the scientists
and lab analysts worldwide who are focused on basic research, drug
discovery and development, food and environmental testing, forensics and
clinical research. With over 25 years of proven innovation, AB SCIEX
excels by listening to and understanding the ever-evolving needs of its
customers to develop reliable, sensitive and intuitive solutions that
continue to redefine what is achievable in routine and complex analysis.
For more information, please go to www.absciex.com.
Follow AB SCIEX on Twitter @ABSCIEX and on Facebook (News - Alert).
AB Sciex Instruments Are For Research Use Only. Not for use in
The trademarks mentioned herein are the property of AB Sciex Pte. Ltd.,
or their respective owners. AB SCIEX™ is being used under license.
© 2014 AB SCIEX.
[ Back To Real Time Communications's Homepage ]